RAV_9671
Friday, April 3, 2026
30.4
C
Bengaluru
Hot topics
Personalizing the Selling – What Pharma Needs to Understand about Customers and their Experiences
"Customer Experience," abbreviated "CX," refers to all the perceptions...
Debasish Banerjee’s Journey from Medical Rep to Chief Compliance Officer
For a person wanting to be a doctor, my...
Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World
Last week, I was in a meeting with the...
Culture and Resistance to Change – A Pharma SFE Adoption Case Study
As an MNC Head, I was one among the...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hot topics
Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead
The latest PharmaTrac report for December 2025 offers a...
Navigating India’s Diverging Health Landscape and Field Force Optimisation
India’s health map is splitting into two distinct opportunity...
Partner Don’t Punish
Articles by Vivek Hattangadi, Genesh Kuriakose, Pankaj Mehrotra, Salil Kallianpur and Jay Mehta
Deep Bhandari: Human capital holds the highest value for organizations
DigiStorm 2018 was held on 11 September at the Lalit Ashok in Bangalore. The event was headlined by Prabir Jha – President & Global Chief People Officer, Cipla. Deep Bhandari – Editorial Board Member, MedicinMan, gives us the highlights of the post-lunch session.
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
Newsletter
Get important news delivered directly to your inbox and stay connected!